148 related articles for article (PubMed ID: 1373210)
1. On the biochemical modulation of 6-mercaptopurine by methotrexate in murine WEHI-3b leukemia cells in vitro.
Liliemark J; Pettersson B; Peterson C
Leuk Res; 1992; 16(3):275-80. PubMed ID: 1373210
[TBL] [Abstract][Full Text] [Related]
2. On the paradoxically concentration-dependent metabolism of 6-mercaptopurine in WEHI-3b murine leukemia cells.
Liliemark J; Pettersson B; Engberg B; Lafolie P; Masquelier M; Peterson C
Cancer Res; 1990 Jan; 50(1):108-12. PubMed ID: 2293545
[TBL] [Abstract][Full Text] [Related]
3. Sequence-, time- and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts.
Bökkerink JP; Bakker MA; Hulscher TW; De Abreu RR; Schretlen ED; van Laarhoven JP; De Bruyn CH
Biochem Pharmacol; 1986 Oct; 35(20):3549-55. PubMed ID: 2429667
[TBL] [Abstract][Full Text] [Related]
4. Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages.
Bökkerink JP; Bakker MA; Hulscher TW; De Abreu RA; Schretlen ED
Biochem Pharmacol; 1988 Jun; 37(12):2321-7. PubMed ID: 2455519
[TBL] [Abstract][Full Text] [Related]
5. The importance of methylthio-IMP for methylmercaptopurine ribonucleoside (Me-MPR) cytotoxicity in Molt F4 human malignant T-lymphoblasts.
Vogt MH; Stet EH; De Abreu RA; Bökkerink JP; Lambooy LH; Trijbels FJ
Biochim Biophys Acta; 1993 Apr; 1181(2):189-94. PubMed ID: 7683208
[TBL] [Abstract][Full Text] [Related]
6. 6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts.
Bökkerink JP; Stet EH; De Abreu RA; Damen FJ; Hulscher TW; Bakker MA; van Baal JA
Biochem Pharmacol; 1993 Apr; 45(7):1455-63. PubMed ID: 7682415
[TBL] [Abstract][Full Text] [Related]
7. [Use of purine rescue pathways by L1210 cells exposed to methotrexate in vitro].
Buesa JM
Rev Esp Oncol; 1982; 29(4):641-7. PubMed ID: 6085740
[TBL] [Abstract][Full Text] [Related]
8. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine.
Dervieux T; Hancock M; Evans W; Pui CH; Relling MV
Leukemia; 2002 Feb; 16(2):209-12. PubMed ID: 11840287
[TBL] [Abstract][Full Text] [Related]
9. Increased concentrations of methylated 6-mercaptopurine metabolites and 6-thioguanine nucleotides in human leukemic cells in vitro by methotrexate.
Giverhaug T; Loennechen T; Aarbakke J
Biochem Pharmacol; 1998 May; 55(10):1641-6. PubMed ID: 9634000
[TBL] [Abstract][Full Text] [Related]
10. Desulfuration of 6-mercaptopurine. The basis for the paradoxical cytotoxicity of thiopurines in cultured human leukemic cells.
Adamson PC; Balis FM; Hawkins ME; Murphy RF; Poplack DG
Biochem Pharmacol; 1993 Nov; 46(9):1627-36. PubMed ID: 8240420
[TBL] [Abstract][Full Text] [Related]
11. Biochemical parameters of mercaptopurine activity in patients with acute lymphoblastic leukemia.
Zimm S; Reaman G; Murphy RF; Poplack DG
Cancer Res; 1986 Mar; 46(3):1495-8. PubMed ID: 2417705
[TBL] [Abstract][Full Text] [Related]
12. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment.
Zaza G; Cheok M; Yang W; Panetta JC; Pui CH; Relling MV; Evans WE
Blood; 2005 Sep; 106(5):1778-85. PubMed ID: 15905191
[TBL] [Abstract][Full Text] [Related]
13. Biochemical basis of the prevention of 6-thiopurine toxicity by the nucleobases, hypoxanthine and adenine.
Hashimoto H; Kubota M; Shimizu T; Takimoto T; Kitoh T; Akiyama Y; Mikawa H
Leuk Res; 1990; 14(11-12):1061-6. PubMed ID: 2280604
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
[TBL] [Abstract][Full Text] [Related]
15. The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX).
Giverhaug T; Loennechen T; Aarbakke J
Gen Pharmacol; 1999 Oct; 33(4):341-6. PubMed ID: 10523073
[TBL] [Abstract][Full Text] [Related]
16. Biochemical effect of three different inhibitors of purine/pyrimidine metabolism on differentiation in HL60 cells.
Ahmed N; Weidemann MJ
Leuk Res; 1995 Apr; 19(4):263-73. PubMed ID: 7538618
[TBL] [Abstract][Full Text] [Related]
17. Effect of methotrexate on the intracellular phosphoribosyl pyrophosphate level and glucose transport of Ehrlich ascites tumor cells in vitro.
Fung KP; Lam WP; Choy YM; Lee CY
Oncology; 1996; 53(1):27-30. PubMed ID: 8570127
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate increases red blood cell concentrations of 6-methylmercaptopurine ribonucleotide in rats in vivo.
Giverhaug T; Fuskevaag OM; Aarbakke J
Cancer Chemother Pharmacol; 1997; 40(4):367-70. PubMed ID: 9225958
[TBL] [Abstract][Full Text] [Related]
19. High performance liquid chromatography analysis of hypoxanthine metabolism in mouse oocyte-cumulus cell complexes: effects of purine metabolic perturbants.
Downs SM
Biol Reprod; 1994 Jun; 50(6):1403-12. PubMed ID: 8080928
[TBL] [Abstract][Full Text] [Related]
20. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.
Dervieux T; Brenner TL; Hon YY; Zhou Y; Hancock ML; Sandlund JT; Rivera GK; Ribeiro RC; Boyett JM; Pui CH; Relling MV; Evans WE
Blood; 2002 Aug; 100(4):1240-7. PubMed ID: 12149204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
